Future of Indian Pharmaceutical Market in this Decade

Why Pharmaceutical exporter in India increased day by day?

India has been the pharmaceutical manufacturing and Pharmaceutical exporter hub for nearly two decades, providing 20% of generic medicines globally by volume, thereby providing affordable medicines to the world. This is an ideal time for industry to provide a boost to the national economy, working hand in hand with the government. It is necessary to engage the government in order to gain a better understanding of the economic infrastructure support required by the industry. As an opportunity and prospect, this industry has the potential to grow at a rate of up to $100 billion per year, making it the second largest economic booster after the information technology industry. The expansion of our reach beyond the United States, where we generate the majority of our revenue, will be the deciding factor in our phenomenal growth. For more click here.

India exports medicines to countries like Australia, Brazil, United Kingdom, United Arab Emirates etc.

1) The deciding factors will be the United Kingdom, Brazil, Africa, Australia and the Middle East.

2) Priority must be given to HIV, Oncology, Neurosciences, and Respiratory drugs.

List of medicines exported from India?

Here is the list of Pharmaceutical exporter provide medicines to all over the world and targeted countries:

  • HIV, 
  • Oncology, 
  • Neurosciences, and 
  • Respiratory drugs.

We have the largest human resource base in terms of chemists and chemical engineers produced by Indian colleges, as well as strong IT support, but we are still lacking in biology despite a large number of biology students, indicating that there is only one Indian company capable of producing bio-similar products on an Where biologics and biosimilars have a much brighter growth outlook. We must recognize that the pharmaceutical industry has already rendered significant service to the world and country. It requires recognition and encouragement.

What our expert says about the Pharmaceutical products and its exporting services?


INDIA PHARMACEUTICAL EXPORTER PRODUCES FOUR OUT OF TEN GENERIC MEDICATIONS IN THE UNITED STATES. This demonstrates that India produces products of the highest quality at the lowest possible price. On the other hand, the industry is over-regulated, as Ms. Kiran Mazumdar (Executive Chairperson-Biocon), authority in the industry, has begun her firm belief and prediction that only pharmaceutical exports could reach $100 billion annually in a very short period of time with 35% of GlaxoSmithKline’s volume comes from India, which is one of the largest multi-national manufacturers. It would be irresponsible not to mention that innovative products come at a cost, particularly in the current environment, where life expectancy (longevity) has increased from 45 years at independence to 68.5 years and is expected to reach 75 years in this decade.

Diseases will take on a variety of forms in this scenario. Not only will anti-infective and respiratory requirements be addressed, but also Alzheimer’s and Parkinson’s disease. The product selection process will be critical to the growth model. According to Mr. Umang Vora (Global CEO, Cipla), the types of products that are going off patent now are quite different from those that went off patent ten years ago. “THE INDUSTRY IS RESHAPING and MUST BE REFURBISHED AND RETOOLED”.

“In this decade, products such as insulin and complex peptides must be prioritized. MNCs are having a difficult time in India because, despite the high volume, they are only able to obtain a small sales value. Quality is the primary issue that Indian companies must address, as international regulatory authorities have observed hindrances despite India’s extensive global presence. The United States will be an ideal market for biosimilar products.

The future aim of Pharmaceutical Export market:

China will be a market to monitor not only due to its size, but also due to the Chinese government’s current liberalization policies, which include easing regulatory requirements, focusing on quality, and also working on financial reimbursement models. This could be very attractive for Indian pharmaceutical exporter companies looking to expand beyond Latin America, North America, the Middle East, Brazil, Australia, UK and Africa.

The impact on the image of Indian pharmacy quality standards must be taken very seriously in light of regulatory, compliance, and warning letter issues raised by the US. Prospectively, these warning letters and issues must be weighed.

Issues should be resolve:

While US companies receive the same number of warning letters as Indian pharmaceutical exporting companies, the image painted for Indian pharmaceutical exporting companies is one of simple suspicion. 46 warning letters were issued to US companies, compared to 12 to India and ten to China, despite the fact that India supplies 40% of the generic drugs used in the United States.

India must modernize its infrastructure and embrace new technologies and automation. The government should de-regulate this excessively regulated market. Financial support will serve as the seed for future innovations. It is comprised of biologics, biosimilars, amino oncology, and neuroscience.

Healthcare financing models such as AYUSHMANN BHARAT are preferable to price control when it comes to evolving disease patterns and treatment.

I am convinced that India will become the world’s pharmacy capital. The world’s most affordable supplier of high-quality medications. Diagnostics for early disease detection and digitalization of healthcare, leveraging India’s expertise in IT, will accelerate India to market leadership and position India as the world’s pharmacy.

Dr. Rajat Bhatt 

(Pharm.D), MBA(IIM)

Executive Director (International Business)

M Care Exports